<DOC>
	<DOCNO>NCT01441973</DOCNO>
	<brief_summary>The purpose study determine whether elotuzumab improve response patient high risk smolder myeloma CD56^dim cell ( marker health body 's immune system )</brief_summary>
	<brief_title>Biomarker Study Elotuzumab High Risk Smoldering Myeloma</brief_title>
	<detailed_description>Intervention model : Dosing sequential</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Key Participants confirm diagnosis , accord criterion International Myeloma Working Group , smolder multiple myeloma , consider high risk accord follow : Serum monoclonal ( M ) protein ≥3 gm/dL bone marrow plasma cell ( BMPC ) ≥10 % Serum M protein 13 g/dL BMPC ≥10 % abnormal free light chain ratio &lt; 0.125 &gt; 8.0 Urine M protein &gt; 200 mg/24 hour , ≥10 % BMPC , serum free light chain ratio ≤0.125 ≥8.0 Key Active multiple myeloma Monoclonal gammopathy undetermined significance Active plasma cell leukemia Positive hepatitis B C virus HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>